EBITDA: Income before interest, taxes, depreciation and amortization.
Viking Therapeutics, Inc. (VKTX) had EBITDA of $-58.47M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-45.63M |
|
-- |
|
-- |
|
$55.47M |
|
$-55.47M |
|
$9.84M |
|
$-45.63M |
|
$-45.63M |
|
$-45.63M |
|
$-45.63M |
|
$-45.63M |
|
$-45.63M |
|
$-55.47M |
|
|
EBITDA |
$-58.47M |
112.07M |
|
112.07M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$866.02M |
|
-- |
|
$0.97M |
|
$866.99M |
|
$19.57M |
|
-- |
|
$0.50M |
|
$20.07M |
|
$846.92M |
|
$846.92M |
|
$846.92M |
|
112.29M |
|
| Cash Flow Statement Financials | |
$-52.33M |
|
$63.24M |
|
$0.35M |
|
$26.68M |
|
$37.94M |
|
$11.26M |
|
$11.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
44.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-52.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.39% |
|
-5.39% |
|
-5.26% |
|
-5.39% |
|
$7.54 |
|
$-0.47 |
|
$-0.47 |
|